Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS

      This paper is only available as a PDF. To read, Please Download here.


      The effects of dronabinol on appetite and weight were evaluated in 139 patients with AIDS-related anorexia and ≥2.3 kg weight loss in a multi-institutional study. Patients were randomized to receive 2.5 mg dronabinol twice daily or placebo. Patients rated appetite, mood, and nausea by using a 100-mm visual analogue scale 3 days weekly. Efficacy was evaluatee in 88 patients. Dronabinol was associated with increased appetite above baseline (38% vs 8% for placebo, P = 0. 015), improvement in mood (10% vs -2%, P = 0. 06), and decreased nausea (20% vs 7%; P = 0. 05). Weight was stable in dronabinol patients, while placebo recipients had a mean loss of 0.4 kg (P = 0.14). Of the dronabinol patients, 22% gained ≥2 kg, compared with 10.5% of placebo recipients (P = 0.11). Side effects were mostly mild to moderate in severity (euphoria, dizziness, thinking abnormalities); there was no difference in discontinued therapy between dronabinol (8.3%) and placebo (4.5%) recipients. Dronabinol was found to be safe and effective for anorexia associated with weight loss in patients with AIDS.

      Key Words


      1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome.
        MMWR. 1987; 36: 3S-15S
        • Hellerstein MK
        Pathophysiology of lean body wasting and nutrient unresponsiveness in HIV/AIDS: therapeutic implications.
        Nutr WV/AIDS. 1992; 1: 17-25
        • Grunfeld C
        • Kotler DP
        Wasting in the acquired immunodeficiency syndrome.
        Semin Liver Dis. 1992; 12: 175-187
        • Kotler DP
        • Tierney AR
        • Wang J
        • Pierson Jr, RN
        Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS.
        Am J Clin Nutr. 1989; 50: 444-447
        • Chlebowski RT
        • Grosvenor MB
        • Bernhard NH
        • Morales LS
        • Bulcavage LM
        Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS.
        Am j Gastroenterol. 1989; 84: 1288-1293
        • Struwe M
        • Kaempfer SH
        • Geiger CJ
        • et al.
        Effect of dronabinol on nutritional status in HIV infection.
        Ann Pharmacother. 1993; 27: 827-831
        • Gorter R
        • Seefried M
        • Volberding P
        Dronabinol effects on weight in patients with HIV infection.
        AIDS. 1992; 6: 127-138
      2. Data on file. Roxane Laboratories, Columbus, OH.

        • Plasse TF
        • Gorter RW
        • Krasnow SH
        • et al.
        Recent clinical experience with dronabinol.
        Pharmacol Biochem Behav. 1991; 40: 695-700
      3. Megace oral suspension full prescribing information. Bristol Myers Squibb, Princeton, NJ.

        • Cat LK
        • Coleman RL
        Treatment for HIV wasting syndrome.
        Ann Pharmacother. 1994; 28: 595-597